
    
      This study will evaluate the time-to-progression (TTP) in patients with metastatic breast
      cancer, receiving 1st line therapy with bevacizumab in combination with paclitaxel and
      gemcitabine.

      Secondary objectives will include response rates and overall survival (OS).
    
  